Abstract
Myelosuppression is one of the most severe and limiting side effects of chemotherapy. Our recent work outlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming dose of the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. Furthermore, by administering sequential quizartinib primed injections of fluorouracil (5-FU), we demonstrated a novel and effective strategy to eliminate disease in two mouse models of quizartinib resistant acute myeloid leukemia (AML).
Original language | English (US) |
---|---|
Article number | e1378156 |
Journal | Molecular and Cellular Oncology |
Volume | 4 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2 2017 |
Externally published | Yes |
Keywords
- FLT3
- acute myeloid leukemia
- chemotherapy
- hematopoietic progenitors
- myelosuppression
- quizartinib
ASJC Scopus subject areas
- Molecular Medicine
- Cancer Research